(Total Views: 301)
Posted On: 05/19/2019 4:22:18 PM
Post# of 154945
Quote:
Misui I have a question. If Pfizer has invested in Maraviroc for many years and probably hundred of millions of dollars why would they want to partner with CYDY? Why not just keep pushing their drug?
Read More: https://investorshangout.com/post/view?id=544...z5oP6loXtv
CYDY has the patents for CCR5/Cancer
Leronlimab beats Maraviroc in the HIV space, no resistance, possibly mono approved, less side effects. Pfizer has to know their days are numbers as we are counting down to Leronlimab being approved.
Combo approval is over 99% yet the market is giving nothing. There will be revenue next year. Mono over 50%, yet nothing, cancer shown in animal studies to work better than maraviroc--which worked in human studies, yet nothing. 20% of cancers are ccr5 positive, this has the potential to be the next big cancer revolution, all the research signs are pointing that way. Yet cydy has a 140M market cap; bluebird bio has a 7B market cap in phase 1/2. At some point the market will self-correct.
(0)
(0)
